Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	10/18/2000
Sex:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	01/01/2017 12:34

Aggressive B-Cell Lymphoma Reflex Panel by FISH, Tissue

ARUP test code 3001495

MYC FISH Result	Positive LSI MYC by FISH result is positive. Testing has been reflexed to BCL2_FISH and BCL6_FISH based on client order. Controls were run and performed as expected. This result has been reviewed and approved by [redacted]
Total Cell Count	752
Scoring Method	Computer Assisted
MYC FISH Reference Number	SP25-5050 A1
MYC FISH Source	L neck mass INTERPRETIVE INFORMATION: MYC Rearrangement, FISH MYC fluorescence in situ hybridization (FISH) analysis is designed to detect 8q24 (MYC) translocations regardless of rearrangement partners. Differentially labeled probes targeting the upstream (5') and downstream (3') flanking regions of the MYC gene were used (Agilent Technologies). When 12 percent or more of the cells evaluated show a classic (typical) abnormal signal pattern, it is considered a positive result. Based on the assay performance during test validation, the test is expected to detect 100 percent of MYC rearrangements in patients with MYC-rearranged lymphomas, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively. MYC rearrangement is seen in a variety of B-cell lymphomas, including diffuse large B-cell lymphomas (DLBCL), Burkitt lymphoma, and "double hit" or "triple hit" lymphomas. Results should be correlated with clinical, morphologic, and immunophenotypic data. Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block. The area(s) for analysis were selected by histopathologic review of a matching hematoxylin- and eosin-stained section. The use of this assay on decalcified tissues has not been validated. Results should be interpreted with caution.

H=High, L=Low, *=Abnormal, C=Critical

Controls performed appropriately.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

IGH-BCL2 Fusion, t(14;18) by FISH

ARUP test code 3001298

BCL2 FISH Result	Positive Controls were run and performed as expected. This result has been reviewed and approved by [redacted]
Total Cell Count	658
Scoring Method	Computer Assisted
BCL2 FISH Reference Number	SP25-5050 A1
BCL2 FISH Source	L neck mass INTERPRETIVE INFORMATION: IGH-BCL2 t(14;18), FISH IGH-BCL2 fluorescence in situ hybridization (FISH) analysis is designed to detect the IGH-BCL2 fusion associated with t(14;18)(q32;q21). Differentially labeled fluorescent probes directed against IGH and BCL2 were used (Agilent Technologies). Fused signals within a cell are considered abnormal signal patterns and are consistent with IGH-BCL2 fusion. If a sample contains single fused signals seen in 21 percent or more of the cells, or two or more fused signals in 6 percent or more of the cells evaluated, it is considered a positive result. Based on the assay performance during test validation, the test is expected to detect 100 percent of IGH-BCL2 rearrangements in patients with IGH-BCL2-rearranged lymphomas, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively. IGH-BCL2 fusion is seen in a variety of B-cell lymphomas including follicular lymphomas, diffuse large B-cell lymphomas (DLBCL), and "double hit" or "triple hit" lymphomas. Results should be correlated with clinical, morphologic, and immunophenotypic data. Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block. The area(s) for analysis were selected by histopathologic review of a matching hematoxylin- and eosin-stained section. Controls performed appropriately. This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

H=High, L=Low, *=Abnormal, C=Critical

BCL6 (3q27) Gene Rearrangement by FISH

ARUP test code 3001311

BCL6 FISH Result	Positive Controls were run and performed as expected. This result has been reviewed and approved by [redacted]
Total Cell Count	732
Scoring Method	Computer Assisted
BCL6 FISH Reference Number	SP25-5050 A1
BCL6 FISH Source	L neck mass

INTERPRETIVE INFORMATION: BCL6 (3q27) Gene Rearrangement, FISH

BCL6 fluorescence in situ hybridization (FISH) analysis is designed to detect 3q27 (BCL6) translocations regardless of rearrangement partners. Differentially labelled probes targeting the upstream (5') and downstream (3') flanking regions of the BCL6 gene were used (Agilent Technologies).

When 12 percent or more of the cells evaluated show an abnormal signal pattern, it is considered a positive result. Some signal patterns other than the classic abnormal pattern may also be present and may be considered abnormal.

BCL6 rearrangement is commonly found in diffuse large B-cell lymphomas (DLBCL) and follicular lymphomas. Results should be correlated with clinical, morphologic and immunophenotypic data. Based on the assay performance during test validation, the test is expected to detect 100 percent of BCL6 rearrangements in patients with BCL6-rearranged lymphomas, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively.

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block. The area(s) for analysis were selected by histopathologic review of a matching hematoxylin- and eosin-stained section.

Controls performed appropriately.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
BCL2 FISH Result	25-070-160958	3/11/2025 3:32:00 PM	3/18/2025 11:38:31 AM	3/19/2025 10:26:00 AM
BCL6 FISH Result	25-070-160958	3/11/2025 3:32:00 PM	3/18/2025 11:38:31 AM	3/19/2025 10:26:00 AM
MYC FISH Result	25-070-160958	3/11/2025 3:32:00 PM	3/14/2025 7:44:27 AM	3/18/2025 11:38:00 AM

H=High, L=Low, *=Abnormal, C=Critical

Total Cell Count	25-070-160958	3/11/2025 3:32:00 PM	3/18/2025 11:38:31 AM	3/19/2025 10:26:00 AM
Total Cell Count	25-070-160958	3/11/2025 3:32:00 PM	3/18/2025 11:38:31 AM	3/19/2025 10:26:00 AM
Total Cell Count	25-070-160958	3/11/2025 3:32:00 PM	3/14/2025 7:44:27 AM	3/18/2025 11:38:00 AM
Scoring Method	25-070-160958	3/11/2025 3:32:00 PM	3/14/2025 7:44:27 AM	3/18/2025 11:38:00 AM
Scoring Method	25-070-160958	3/11/2025 3:32:00 PM	3/18/2025 11:38:31 AM	3/19/2025 10:26:00 AM
Scoring Method	25-070-160958	3/11/2025 3:32:00 PM	3/18/2025 11:38:31 AM	3/19/2025 10:26:00 AM
BCL2 FISH Reference Number	25-070-160958	3/11/2025 3:32:00 PM	3/18/2025 11:38:31 AM	3/18/2025 11:39:00 AM
BCL6 FISH Reference Number	25-070-160958	3/11/2025 3:32:00 PM	3/18/2025 11:38:31 AM	3/18/2025 11:39:00 AM
MYC FISH Reference Number	25-070-160958	3/11/2025 3:32:00 PM	3/14/2025 7:44:27 AM	3/14/2025 7:12:00 PM
BCL2 FISH Source	25-070-160958	3/11/2025 3:32:00 PM	3/18/2025 11:38:31 AM	3/18/2025 11:39:00 AM
BCL6 FISH Source	25-070-160958	3/11/2025 3:32:00 PM	3/18/2025 11:38:31 AM	3/18/2025 11:39:00 AM
MYC FISH Source	25-070-160958	3/11/2025 3:32:00 PM	3/14/2025 7:44:27 AM	3/14/2025 7:12:00 PM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical